Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.75 |
| ▸ | TERT | O14746 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769834 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL30122220 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL29362454 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL17268344 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL8613042 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL8612856 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL16983788 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL30632043 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL16979766 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL9160842 | 0.93 | DTYMK (0.83) | DTYMKTERTPOLBENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4377456-A2 | GENE EDITING SYSTEMS COMPRISING A NUCLEASE AND USES THEREOF | Arbor Biotechnologies, Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| US-20230059141-A1 | GENE EDITING SYSTEMS COMPRISING A NUCLEASE AND USES THEREOF | Arbor Biotechnologies, Inc. | 2023-02-23 | — | — | US | claimed |
| WO-2023010084-A2 | GENE EDITING SYSTEMS COMPRISING A NUCLEASE AND USES THEREOF | Arbor Biotechnologies, Inc. (US) | 2023-02-02 | — | — | WO | claimed |
| EP-4735603-A2 | GUIDE RNA COMPOSITIONS | nChroma Bio, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | APTAH BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4692338-A1 | CAS12 PROTEIN AND USE THEREOF | Guangzhou Reforgene Medicine Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | APTAH BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260009052-A1 | CAS12 PROTEINS AND USES THEREOF | GUANGZHOU REFORGENE MEDICINE CO., LTD. (CN) | 2026-01-08 | — | — | US | disclosed |
| US-20250388597-A1 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250369048-A1 | LABELING OF NUCLEIC ACID MOLECULE BY INTERSTRAND CROSSLINKED DOUBLE-STRAND DNA | HITACHI, LTD. (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4652277-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2023010084-A2 | GENE EDITING SYSTEMS COMPRISING A NUCLEASE AND USES THEREOF | Arbor Biotechnologies, Inc. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023288111-A2 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATION | APTAH BIO, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022265032-A1 | LABELING OF NUCLEIC ACID MOLECULE BY INTERSTRAND CROSSLINKED DOUBLE-STRAND DNA | 株式会社日立製作所 | 2022-12-22 | — | — | WO | disclosed |
| US-20220396812-A1 | RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-12-15 | — | — | US | disclosed |
| US-20220348985-A1 | FORCED INTERCALATION (FIT)-APTAMERS: PROBES BASED ON FORCED INTERCALATION | NORTHWESTERN UNIVERSITY | 2022-11-03 | — | — | US | disclosed |
| EP-4039690-A1 | A SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHORAMIDOCHLORIDATE, A METHOD AND A PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022140577-A2 | COMPOSITIONS AND METHODS FOR EPIGENETIC EDITING | CHROMA MEDICINE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11371062-B2 | RNA-guided nucleic acid modifying enzymes and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022104381-A1 | A MINIMAL CRISPRi/a SYSTEM FOR TARGETED GENOME REGULATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | RPRD2, RTCB, UPF1 | DTYMK 204/4885TERT 723/4885POLB 224/4885 |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRNP, UPF1, FUS | DTYMK 533/4885TERT 397/4885POLB 387/4885 |
| US-20250388597-A1 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | PCNA, DDB1, DCLRE1A | DTYMK 573/4885TERT 2525/4885POLB 101/4885 |
| US-20260009052-A1 | CAS12 PROTEINS AND USES THEREOF | RBM12, STING1, TTLL12 | DTYMK 644/4885TERT 3318/4885POLB 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.